Get the Stockscreener App
22.45
0.43%
0.0946
Castle Biosciences Inc stock is traded at $22.45, with a volume of 181.78K.
It is up +0.43% in the last 24 hours and up +3.87% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
See More
Previous Close:
$22.36
Open:
$22.38
24h Volume:
181.78K
Relative Volume:
0.39
Market Cap:
$651.24M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-10.44
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
-4.81%
1M Performance:
+3.87%
6M Performance:
+6.68%
1Y Performance:
-32.93%
1-Day Range:
$22.11
$22.82
1-Week Range:
$22.11
$24.00
52-Week Range:
$14.59
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
22.45 | 648.63M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
527.89 | 198.56B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
207.09 | 147.61B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
639.57 | 50.96B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.71 | 39.13B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
204.20 | 34.81B | 15.70B | 1.24B | 2.01B | 6.9036 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Risk adjusted return profile for Castle Biosciences Inc. analyzedEntry Point & AI Powered Market Entry Ideas - newser.com
When is the best time to exit Castle Biosciences Inc.July 2025 Chart Watch & Community Trade Idea Sharing Platform - newser.com
How high can Castle Biosciences Inc. stock goQuarterly Trade Summary & Real-Time Sentiment Analysis - newser.com
Is Castle Biosciences Inc. stock attractive for income investors2025 Year in Review & Reliable Entry Point Trade Alerts - newser.com
Can swing trading help recover from Castle Biosciences Inc. lossesMarket Volume Report & Long Hold Capital Preservation Tips - newser.com
Using data tools to time your Castle Biosciences Inc. exitWeekly Investment Recap & Free AI Powered Buy and Sell Recommendations - newser.com
Castle Biosciences to Release Third Quarter 2025 Financial - GlobeNewswire
Will Castle Biosciences Inc. stock remain a Wall Street favoriteWeekly Profit Analysis & Stock Portfolio Risk Management - newser.com
Castle Biosciences, Inc. to Announce Third Quarter 2025 Financial Results on November 3 - Quiver Quantitative
Nov. 3 webcast: Castle Biosciences to release Q3 results and host conference call at 4:30 PM ET - Stock Titan
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025 - Sahm
New Data Demonstrates Significant & Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Dec... - ADVFN
Is Castle Biosciences Inc. stock poised for growthDividend Hike & Proven Capital Preservation Tips - newser.com
Is this a good reentry point in Castle Biosciences Inc.July 2025 PostEarnings & Consistent Return Investment Signals - newser.com
What drives Castle Biosciences Inc stock priceCup and Handle Formations & Free Expert Stock Watchlists - earlytimes.in
How to integrate Castle Biosciences Inc. into portfolio analysis toolsMarket Performance Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Weiss Ratings Reiterates "Sell (E+)" Rating for Castle Biosciences (NASDAQ:CSTL) - MarketBeat
Castle Biosciences Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Castle Biosciences CEO Maetzold sells $30,234 in shares - Investing.com
Will Castle Biosciences Inc. stock pay special dividendsGDP Growth & Weekly Top Gainers Trade List - newser.com
How Castle Biosciences Inc. stock reacts to Fed rate cuts2025 Price Action Summary & Weekly Market Pulse Alerts - newser.com
Order flow analysis tools used on Castle Biosciences Inc.2025 Pullback Review & Daily Stock Trend Reports - newser.com
Analyzing net buyer seller activity in Castle Biosciences Inc.Trade Volume Summary & Verified Technical Trade Signals - newser.com
Is Castle Biosciences Inc a good long term investmentBollinger Bands Signals & Low Risk Investment Growth - earlytimes.in
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine - The Manila Times
Castle Biosciences’ Founder, President and CEO Derek - GlobeNewswire
Selected from 586 Executives: Castle Biosciences' Derek Maetzold Crowned CEO of the Year 2025 - Stock Titan
User - FinancialContent
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
What analysts say about Castle Biosciences Inc stockSmall Cap Stock Opportunities & High Profit Market Tips - Early Times
Strs Ohio Takes $366,000 Position in Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):